Hyperglycemia abolishes the endothelial-dependent antihypertrophic efficacy of bradykinin in ventricular myocytes, suggesting a potential mechanism for reduced efficacy of ACE inhibitors in diabetic patients.
High glucose may blunt bradykinin antihypertrophy in vitro; leaves open a mechanism for reduced ACE inhibitor efficacy in diabetic cardiomyopathy.
Bradykinin inhibits hypertrophy of rat ventricular myocytes, but only in the presence of endothelial cells. 2. The influence of hyperglycaemia on the ability of bradykinin to prevent hypertrophy was investigated in adult rat ventricular myocytes cocultured with bovine aortic endothelial cells (BAEC). 3. In myocytes cocultured with normal BAEC, angiotensin II (AngII; 1 mumol/L) significantly increased [3H]-phenylalanine incorporation (an in vitro marker of hypertrophy) by 32 +/- 2%. This was abolished by bradykinin (10 mumol/L). 4. Pretreatment of BAEC with high glucose (25 mmol/L for 24 h) prior to coculture with myocytes reduced the antihypertrophic effect of bradykinin, but did not modulate the hypertrophic effect of AngII. 5. Pretreatment of BAEC with hyperglycaemia abolishes the antihypertrophic efficacy of bradykinin in rat ventricular myocytes cocultured with BAEC. This has implications for the action of angiotensin-converting enzyme inhibitors.
No takes yet. Share an insight, caveat, or question.
Rosenkranz et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: